immunocellular therapeutics ltd  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report immunocellular therapeutics ltd  product pipeline review   published by global markets direct product code  published may   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license immunocellular therapeutics ltd  product pipeline review   published may   content info  pages description summary global markets directs immunocellular therapeutics ltd  product pipeline review   provides an overview of the immunocellular therapeutics ltds pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of immunocellular therapeutics ltds complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of immunocellular therapeutics ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of immunocellular therapeutics ltds human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the immunocellular therapeutics ltds pipeline products reasons to buy evaluate immunocellular therapeutics ltds strategic position with total access to detailed information on its product pipeline assess the growth potential of immunocellular therapeutics ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the immunocellular therapeutics ltds rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of immunocellular therapeutics ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of immunocellular therapeutics ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of immunocellular therapeutics ltd and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures immunocellular therapeutics ltd snapshot immunocellular therapeutics ltd overview key information key facts immunocellular therapeutics ltd  research and development overview key therapeutic areas immunocellular therapeutics ltd  pipeline review pipeline products by stage of development pipeline products  monotherapy immunocellular therapeutics ltd  pipeline products glance immunocellular therapeutics ltd  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities immunocellular therapeutics ltd  early stage pipeline products preclinical productscombination treatment modalities immunocellular therapeutics ltd  drug profiles ict product description mechanism of action rd progress ict product description mechanism of action rd progress ict product description mechanism of action rd progress ict product description mechanism of action rd progress stem cell therapies for cancer product description mechanism of action rd progress immunocellular therapeutics ltd  pipeline analysis immunocellular therapeutics ltd  pipeline products by target immunocellular therapeutics ltd  pipeline products by route of administration immunocellular therapeutics ltd  pipeline products by molecule type immunocellular therapeutics ltd  pipeline products by mechanism of action immunocellular therapeutics ltd  recent pipeline updates immunocellular therapeutics ltd  dormant projects immunocellular therapeutics ltd  company statement immunocellular therapeutics ltd  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables immunocellular therapeutics ltd key information immunocellular therapeutics ltd key facts immunocellular therapeutics ltd  pipeline by indication  immunocellular therapeutics ltd  pipeline by stage of development  immunocellular therapeutics ltd  monotherapy products in pipeline  immunocellular therapeutics ltd  phase ii  immunocellular therapeutics ltd  phase i  immunocellular therapeutics ltd  preclinical  immunocellular therapeutics ltd  pipeline by target  immunocellular therapeutics ltd  pipeline by route of administration  immunocellular therapeutics ltd  pipeline by molecule type  immunocellular therapeutics ltd  pipeline products by mechanism of action  immunocellular therapeutics ltd  recent pipeline updates  immunocellular therapeutics ltd  dormant developmental projects immunocellular therapeutics ltd subsidiaries list of figures immunocellular therapeutics ltd  pipeline by top  indication  immunocellular therapeutics ltd  pipeline by stage of development  immunocellular therapeutics ltd  monotherapy products in pipeline  immunocellular therapeutics ltd  pipeline by top  target  immunocellular therapeutics ltd  pipeline by top  route of administration  immunocellular therapeutics ltd  pipeline by top  molecule type  immunocellular therapeutics ltd  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising events  presentations  immunocellular contact about us immunocellular history management board of directors contact us technology cancer immunotherapy dendritic cellbased immunotherapeutics stemtot cell platform manufacturing process immunocellular advantages publications resources pipeline ict ict ict stemtot cell investors press releases events  presentations stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile financial information key ratios sec filings corporate governance board of directors committee composition shareholder briefcase rss feeds snapshot business development menu about us immunocellular history management board of directors contact us technology cancer immunotherapy dendritic cellbased immunotherapeutics stemtot cell platform manufacturing process immunocellular advantages publications resources pipeline ict ictict stemtot cell investors press releases events  presentations corporate governance board of directors committee composition financial information key ratios sec filings stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile shareholder briefcase rss feeds snapshot business development investors events  presentations investors home press releases events  presentations stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile financial information key ratios sec filings corporate governance board of directors committee composition shareholder briefcase rss feeds snapshot upcoming events details on upcoming events are not yet available conferences and webcasts date event details june    am et marcum  microcap conference speaker anthony j gringeri phd president and chief executive officer listen to webcast march    pm pt immunocellular therapeutics fourth quarter  financial results listen to webcast view additional information live call   tollfree international dialin   conference code   add file to briefcase about us technology pipeline investors business development terms of use  privacy policy  contact copyright  by immunocellular therapeutics ltdall rights reserved    login immunocellular therapeutics ltd imuck company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile immunocellular therapeutics ltd imuck related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse imuck on american stock exchange usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description immunocellular therapeutics ltd incorporated on march   is a clinicalstage biotechnology company the company is developing immunebased therapies for the treatment of cancers the companys cancer immunotherapies target cancer stem cells cscs which are the drivers of tumor growth and disease recurrence its product candidate is ict which is in phase iii testing in addition the company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer its other product candidates are ict for ovarian cancer and ict for recurrent glioblastoma multiforme gbmictthe companys lead product candidate ict is a dendritic cell dc vaccine for the treatment of newly diagnosed gbm a type of brain cancer ict activates a patients immune system to target over six different tumorassociated antigens ict is involved in a clinical trial designed as a doubleblind placebocontrolled  randomized multicenter evaluation of the safety and efficacy of ict in patients with newly diagnosed gbm ict targets approximately six different tumorassociated antigens the therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed gbmictict is a vaccine that targets approximately seven tumorassociated antigens expressed on ovarian cancer cells ict is a dcbased vaccine targeting cscs and cancer antigens for the treatment of recurrent ovarian cancer the company has completed the phase ii trials of ictictthe company is developing ict a dendritic cell dcbased vaccine targeting cd cscs for the treatment of recurrent gbm and other solid tumor cancers including ovarian pancreatic and breast cancers the product candidate is in phase i enrolling patientstagethe company competes with roche group amgen inc merck  co inc novartis ag glaxosmithkline plc celgene corporation bristolmyers squibb company oncothyreon inc galena biopharma inc bavarian nordic as kite pharma inc juno therapeutics inc immunovaccine inc prima biomed ltd dc prime bv celldex therapeutics inc northwest biotherapeutics inc agenus inc oncomed pharmaceuticals inc verastem inc stemline therapeutics inc and infinity pharmaceuticals inc » full overview of imuck company address immunocellular therapeutics ltd  calabasas rd ste calabasas   ca    p f  company web links home page officers  directors name compensation anthony gringeri  david fractor  rahul singhvi  john yu  anthony lapointe  » more officers  directors immunocellular therapeutics ltd news briefempery asset management reports  pct passive stake in immunocellular therapeutics  sec filing‍​ jul   briefimmunocellular therapeutics announces pricing of public offering of convertible preferred stock and warrants jul   briefimmunocellular therapeutics receives notice from nyse market for noncompliance with continued listing standards jun   briefimmunocellular to suspend patient randomization for ict phase  trial jun   briefimmunocellular therapeutics reports data from ict phase  trial in recurrent glioblastoma jun   » more imuck news related topics stocksstock screenerhealthcarebiotechnology  medical research immunocellular therapeutics ltd  product pipeline review      about us blog contact us faq  usd eur gbp usd ▼ usd eur gbp € eur  usd £ gbp rest of world us toll free  advanced price from €eurusd£gbp view pricing you are here home  categories  company reports select a format  €eurusd£gbp single user electronic pdf  this is a single user license allowing one specific user access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp site license electronic pdf  this is a site license allowing all users within a given geographical location of your organisation access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp enterprisewide electronic pdf  this is an enterprise license allowing all employees within your organisation access to the product the report will be emailed to you the report is sent in pdf format  add to basket order by fax need a quote  our clients have a question email us view faqs recently viewed products partner of research and marketsvaccinating  children in  why choose research and markets worlds largest selection trusted by the best customer focused safe  secure i recently ordered a book from research and markets via their website shortly after ordering the book i received a message from the research and markets orders department stating that payment had not been received for the book my first thought was credit card fraud i called orders department and was connected immediately with maria o’toole maria was extremely helpful in resolving the payment question maria suggested that since research and markets is located in dublin ireland and i am located in seattle washington my credit card company might have placed a hold on the payment i checked with my card company and this was indeed the case i corrected the hold on the payment and informed maria maria confirmed that the payment transaction had been completed and assured me that the book would be delivered in a timely manner i truly appreciate the ease with which i was able to contact a live person quickly and resolve the issue easily i highly recommend research and markets for their depth and breadth of research materials and their excellent customer service read more mr brad kelln sr project manager mcbride construction resources inc immunocellular therapeutics ltd  product pipeline review   id  company profile may   pages global markets direct immunocellular therapeutics ltd description table of contents samples formats  of  login to access executive summary printer friendly printable pdf brochure send to a friend immunocellular therapeutics ltd  product pipeline review  summarythis ‘immunocellular therapeutics ltd  product pipeline review  ’ provides an overview of the immunocellular therapeutics ltd’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of immunocellular therapeutics ltd’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsthis report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from this proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by this team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of immunocellular therapeutics ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of immunocellular therapeutics ltd’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the immunocellular therapeutics ltd’s pipeline productsreasons to buy evaluate immunocellular therapeutics ltd’s strategic position with total access to detailed information on its product pipeline assess the growth potential of immunocellular therapeutics ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the immunocellular therapeutics ltd’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of immunocellular therapeutics ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of immunocellular therapeutics ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of immunocellular therapeutics ltd and identify potential opportunities in those areas avoid intellectual property rights related issues show less read more note product cover images may vary from those shown  of  login to access executive summary printer friendly printable pdf brochure send to a friend list of tableslist of figuresimmunocellular therapeutics ltd snapshotimmunocellular therapeutics ltd overviewkey informationkey factsimmunocellular therapeutics ltd  research and development overviewkey therapeutic areasimmunocellular therapeutics ltd  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapyimmunocellular therapeutics ltd  pipeline products glanceimmunocellular therapeutics ltd  clinical stage pipeline productsphase ii productscombination treatment modalitiesphase i productscombination treatment modalitiesimmunocellular therapeutics ltd  early stage pipeline productspreclinical productscombination treatment modalitiesimmunocellular therapeutics ltd  drug profilesictproduct descriptionmechanism of actionrd progressictproduct descriptionmechanism of actionrd progressictproduct descriptionmechanism of actionrd progressictproduct descriptionmechanism of actionrd progressstem cell therapies for cancerproduct descriptionmechanism of actionrd progressimmunocellular therapeutics ltd  pipeline analysisimmunocellular therapeutics ltd  pipeline products by targetimmunocellular therapeutics ltd  pipeline products by route of administrationimmunocellular therapeutics ltd  pipeline products by molecule typeimmunocellular therapeutics ltd  pipeline products by mechanism of actionimmunocellular therapeutics ltd  recent pipeline updatesimmunocellular therapeutics ltd  dormant projectsimmunocellular therapeutics ltd  company statementimmunocellular therapeutics ltd  locations and subsidiarieshead officeother locations  subsidiariesappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimer list of tablesimmunocellular therapeutics ltd key informationimmunocellular therapeutics ltd key factsimmunocellular therapeutics ltd  pipeline by indication immunocellular therapeutics ltd  pipeline by stage of development immunocellular therapeutics ltd  monotherapy products in pipeline immunocellular therapeutics ltd  phase ii immunocellular therapeutics ltd  phase i immunocellular therapeutics ltd  preclinical immunocellular therapeutics ltd  pipeline by target immunocellular therapeutics ltd  pipeline by route of administration immunocellular therapeutics ltd  pipeline by molecule type immunocellular therapeutics ltd  pipeline products by mechanism of action immunocellular therapeutics ltd  recent pipeline updates immunocellular therapeutics ltd  dormant developmental projectsimmunocellular therapeutics ltd subsidiaries list of figuresimmunocellular therapeutics ltd  pipeline by top  indication immunocellular therapeutics ltd  pipeline by stage of development immunocellular therapeutics ltd  monotherapy products in pipeline immunocellular therapeutics ltd  pipeline by top  target immunocellular therapeutics ltd  pipeline by top  route of administration immunocellular therapeutics ltd  pipeline by top  molecule type immunocellular therapeutics ltd  pipeline products by top  mechanism of action  note product cover images may vary from those shown  of  loading  of  note product cover images may vary from those shown related products immunocellular therapeutics ltd imuc  financial and strategic swot analysis review  swot analysis july  from €eurusd£gbp immunofrontier inc  product pipeline review    company profile june  from €eurusd£gbp immunogen inc  product pipeline review    company profile august  from €eurusd£gbp artielle immunotherapeutics inc  product pipeline review    company profile december  from €eurusd£gbp immunobiology ltd  product pipeline review    company profile october  from €eurusd£gbp immunobiology limited  product pipeline review    company profile july  from €eurusd£gbp q  earnings call  immunocellular therapeutics ltd  earnings transcript  earnings transcript march  €eurusd£gbp intracellular therapies inc  product pipeline review    company profile april  from €eurusd£gbp sorrento therapeutics inc  product pipeline review    company profile june  from €eurusd£gbp immunomic therapeutics inc  product pipeline review    company profile february  from €eurusd£gbp close immunocellular therapeutics ltd  product pipeline review   close ask a question required information product immunocellular therapeutics ltd  product pipeline review   your question your contact details title mr mrs dr miss ms prof first name last name email address country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe phone number                                                                                                                                                                                                                                    we request your telephone number so we can contact you in the event we have difficulty reaching you via email we aim to respond to all questions on the same business day close send to a friend  required information friends details full name email address message to friend your contact details full name email address close request a quote please complete the below form and click send request to obtain a pdf quotation and order form this document will be available for immediate download and will also be emailed to you  required information your address address  address  address  city postalzip code country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe state your details title mr mrs dr miss ms prof first name last name organisation email address phone number                                                                                                                                                                                                                                    po number if applicable product format license format properties price single user electronic pdf the report will be emailed to you the report is sent in pdf format this is a single user license allowing one specific user access to the product €eurusd£gbp site license electronic pdf the report will be emailed to you the report is sent in pdf format this is a site license allowing all users within a given geographical location of your organisation access to the product €eurusd£gbp enterprisewide electronic pdf the report will be emailed to you the report is sent in pdf format this is an enterprise license allowing all employees within your organisation access to the product €eurusd£gbp  the price quoted above is only valid for  days please submit your order within that time frame to avail of this price as all prices are subject to change immunocellular therapeutics’ immunotherapy product pipeline overview contact home about us immunocellular history management board of directors contact us technology cancer immunotherapy dendritic cellbased immunotherapeutics stemtotcell platform manufacturing process immunocellular advantages publications resources pipeline ict ict ict stemtotcell investors press releases events  presentations stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile financial information key ratios sec filings corporate governance board of directors committee composition shareholder briefcase rss feeds mobile investor snapshot downloads business development menu homeabout us immunocellular historymanagementboard of directorscontact us technology cancer immunotherapydendritic cellbased immunotherapeuticsstemtotcell platformmanufacturing processimmunocellular advantagespublicationsresources pipeline ictictictstemtotcell investors press releasesevents  presentationsstock information historic stock lookupinvestment calculatordividend policyanalyst coverageownership profile financial information key ratios sec filingscorporate governance board of directorscommittee composition shareholder briefcase rss feedsmobile investorsnapshotdownloads business development pipeline immunocellular therapeutics  is developing immunebased therapies for the treatment of brain and other cancers immunocellulars pipeline includes a stemtotcell research program which engineers hematopoietic stem cells to generate cytotoxic t cells ict a patientspecific dendritic cellbased immunotherapy targeting cd found in recurrent glioblastoma and ict a patientspecific dendritic cellbased immunotherapy targeting ovarian cancer immunocellular recently suspended further patient randomization in its phase  trial of ict in hlaa patients while it pursues a collaborative arrangement or acquisition of its ict program home about us technology pipeline investors business development terms of use  privacy policy  contact copyright  by immunocellular therapeutics ltdall rights reserved    login immunocellular therapeutics’ immunotherapy product pipeline overview contact home about us immunocellular history management board of directors contact us technology cancer immunotherapy dendritic cellbased immunotherapeutics stemtotcell platform manufacturing process immunocellular advantages publications resources pipeline ict ict ict stemtotcell investors press releases events  presentations stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile financial information key ratios sec filings corporate governance board of directors committee composition shareholder briefcase rss feeds mobile investor snapshot downloads business development menu homeabout us immunocellular historymanagementboard of directorscontact us technology cancer immunotherapydendritic cellbased immunotherapeuticsstemtotcell platformmanufacturing processimmunocellular advantagespublicationsresources pipeline ictictictstemtotcell investors press releasesevents  presentationsstock information historic stock lookupinvestment calculatordividend policyanalyst coverageownership profile financial information key ratios sec filingscorporate governance board of directorscommittee composition shareholder briefcase rss feedsmobile investorsnapshotdownloads business development pipeline immunocellular therapeutics  is developing immunebased therapies for the treatment of brain and other cancers immunocellulars pipeline includes a stemtotcell research program which engineers hematopoietic stem cells to generate cytotoxic t cells ict a patientspecific dendritic cellbased immunotherapy targeting cd found in recurrent glioblastoma and ict a patientspecific dendritic cellbased immunotherapy targeting ovarian cancer immunocellular recently suspended further patient randomization in its phase  trial of ict in hlaa patients while it pursues a collaborative arrangement or acquisition of its ict program home about us technology pipeline investors business development terms of use  privacy policy  contact copyright  by immunocellular therapeutics ltdall rights reserved    login investor relations  immunocellular contact about us immunocellular history management board of directors contact us technology cancer immunotherapy dendritic cellbased immunotherapeutics stemtot cell platform manufacturing process immunocellular advantages publications resources pipeline ict ict ict stemtot cell investors press releases events  presentations stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile financial information key ratios sec filings corporate governance board of directors committee composition shareholder briefcase rss feeds snapshot business development menu about us immunocellular history management board of directors contact us technology cancer immunotherapy dendritic cellbased immunotherapeutics stemtot cell platform manufacturing process immunocellular advantages publications resources pipeline ict ictict stemtot cell investors press releases events  presentations corporate governance board of directors committee composition financial information key ratios sec filings stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile shareholder briefcase rss feeds snapshot business development investors investor relations investors home press releases events  presentations stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile financial information key ratios sec filings corporate governance board of directors committee composition shareholder briefcase rss feeds snapshot immunocellular therapeutics ltd is a los angelesbased clinicalstage company that is developing immunebased therapies for the treatment of brain and other cancers immunocellulars pipeline includes a stemtotcell research program which engineers hematopoietic stem cells to generate cytotoxic t cells ict a patientspecific dendritic cellbased immunotherapy targeting cd found in recurrent glioblastoma and ict a patientspecific dendritic cellbased immunotherapy targeting ovarian cancer immunocellular recently suspended further patient randomization in its phase  trial of ict in hlaa patients while it pursues a collaborative arrangement or acquisition of its ict program intra  mo  mo  yr press releases july   immunocellular therapeutics announces pricing of public offering of convertible preferred stock and warrants june   immunocellular therapeutics receives notice from nyse mkt for noncompliance with continued listing standards view all press releases » events  presentations june   at  am et marcum  microcap conference march   at  pm pt immunocellular therapeutics fourth quarter  financial results view all events  presentations » about us technology pipeline investors business development terms of use  privacy policy  contact copyright  by immunocellular therapeutics ltdall rights reserved    login immunocellular therapeutics ltd is a clinicalstage biotechnology company contact home about us immunocellular history management board of directors contact us technology cancer immunotherapy dendritic cellbased immunotherapeutics stemtotcell platform manufacturing process immunocellular advantages publications resources pipeline ict ict ict stemtotcell investors press releases events  presentations stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile financial information key ratios sec filings corporate governance board of directors committee composition shareholder briefcase rss feeds mobile investor snapshot downloads business development menu homeabout us immunocellular historymanagementboard of directorscontact us technology cancer immunotherapydendritic cellbased immunotherapeuticsstemtotcell platformmanufacturing processimmunocellular advantagespublicationsresources pipeline ictictictstemtotcell investors press releasesevents  presentationsstock information historic stock lookupinvestment calculatordividend policyanalyst coverageownership profile financial information key ratios sec filingscorporate governance board of directorscommittee composition shareholder briefcase rss feedsmobile investorsnapshotdownloads business development about us immunocellular therapeutics ltd  is a los angelesbased clinicalstage company that is developing immunebased therapies for the treatment of brain and other cancers immunocellulars pipeline includes a stemtotcell research program which engineers hematopoietic stem cells to generate cytotoxic t cells ict a patientspecific dendritic cellbased immunotherapy targeting cd found in recurrent glioblastoma and ict a patientspecific dendritic cellbased immunotherapy targeting ovarian cancer immunocellular recently suspended further patient randomization in its phase  trial of ict in hlaa patients while it pursues a collaborative arrangement or acquisition of its ict program ict is a dendritic cellbased immunotherapy targeting multiple tumorassociated antigens on glioblastoma stem cells immunocellular recently suspended further patient randomization in its phase  trial of ict in hlaa patients while it pursues a collaborative arrangement or acquisition of its ict program ict is a dc immunotherapeutic that targets cd an antigen commonly associated with cancer stem cells cscs we are conducting a patient phase  clinical trial in patients with recurrent glioblastoma ict is a dc immunotherapeutic that targets seven different antigens associated with ovarian cancer including those expressed by cscs a phase  trial is awaiting a partnership or other financing to proceed immunocellular’s goal is to become an industryleading independent commercialstage cancer immunotherapy company we have a development pipeline of therapeutically important commercially attractive product candidates and a highly productive proprietary cancer immunotherapy platform these assets have the potential to transform the treatment of cancer benefit patients and create value for our stakeholders home about us technology pipeline investors business development terms of use  privacy policy  contact copyright  by immunocellular therapeutics ltdall rights reserved    login imucnyse mkt llc stock quote  immunocellular therapeutics ltd  bloomberg markets error could not add to watchlist x  watchlist immunocellular therapeutics ltd imucus nyse mkt llc usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  immunocellular therapeutics announces pricing of public offering of convertible preferred stock and warrants  immunocellular therapeutics receives notice from nyse mkt for noncompliance with continued listing standards  june  deadline lundin law pc announces a securities class action lawsuit against immunocellular therapeutics ltd and encou  friday june  deadline khang  khang llp announces a securities class action lawsuit against immunocellular therapeutics ltd  the klein law firm reminds investors of a class action filed on behalf of immunocellular therapeutics ltd shareholders and a  friday deadline lundin law pc announces a securities class action lawsuit against immunocellular therapeutics ltd and encour  imuc investor alert the law offices of vincent wong reminds investors of a class action involving immunocellular therapeutics  equity alert levi  korsinsky llp reminds immunocellular therapeutics ltd shareholders of a class action lawsuit and a lead  immunocellular therapeutics provides update on strategic review and decision to suspend further patient randomization for ict  law offices of howard g smith reminds immunocellular therapeutics ltd investors of pending lawsuit and upcoming lead there are currently no press releases for this ticker please check back later profile immunocellular therapeutics ltd is a development stage company that seeks to develop imaging devices with medical diagnostic applications address  burbank blvdwoodland hills ca united states phone  website wwwimuccom executives board members gary s titus chairmansecretary anthony j gringeri tony presidentceo david e fractor chief financial officer steven j swanson senior vpresearch marta schilling vpcell therapy manufacturing show more immunocellular therapeutics’ work in industryleading nextgeneration cancer immunotherapies contact home about us immunocellular history management board of directors contact us technology cancer immunotherapy dendritic cellbased immunotherapeutics stemtotcell platform manufacturing process immunocellular advantages publications resources pipeline ict ict ict stemtotcell investors press releases events  presentations stock information historic stock lookup investment calculator dividend policy analyst coverage ownership profile financial information key ratios sec filings corporate governance board of directors committee composition shareholder briefcase rss feeds mobile investor snapshot downloads business development menu homeabout us immunocellular historymanagementboard of directorscontact us technology cancer immunotherapydendritic cellbased immunotherapeuticsstemtotcell platformmanufacturing processimmunocellular advantagespublicationsresources pipeline ictictictstemtotcell investors press releasesevents  presentationsstock information historic stock lookupinvestment calculatordividend policyanalyst coverageownership profile financial information key ratios sec filingscorporate governance board of directorscommittee composition shareholder briefcase rss feedsmobile investorsnapshotdownloads business development if you are a patient or doctor  and would like to speak to someone about our clinical programs  please contact clintrialsimuccom     press releases tuesday july   immunocellular therapeutics announces pricing of public offering read more  thursday june   immunocellular therapeutics receives notice from nyse mkt read more  thursday june   immunocellular therapeutics announces data from ict phase  trial read more  events  presentations june    immunocellular therapeutics to present at marcum microcap conference listen to webcast additional information   home about us technology pipeline investors business development terms of use  privacy policy  contact copyright  by immunocellular therapeutics ltdall rights reserved    login microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft imuc  stock quote for immunocellular therapeutics ltd  msn money msn back to msn home money web search sign in change language  content américa latina español argentina español australia english belgië nederlands belgique français brasil português canada english canada français chile español colombia español danmark dansk deutschland deutsch españa español france français india english indonesia bahasa indonesia ireland english italia italiano malaysia english méxico español nederland nederlands new zealand english norge norsk bokmål österreich deutsch perú español philippines english polska polski portugal português schweiz deutsch singapore english south africa english suisse français suomi suomi sverige svenska türkiye türkçe united arab emirates english united kingdom english united states english united states español venezuela español việt nam tiếng việt ελλάδα ελληνικά россия pусский ישראל עברית‏ الإمارات العربية المتحدة العربية‏ المملكة العربية السعودية العربية‏ مصر العربية‏ ไทย ไทย 한국 한국어      語   switch to latino español feedback help adchoices immunocellular therapeutics ltd amex imuc us markets closed adchoices  ▼   after hours     july    pm edt delayed  minutes source nasdaq currency in usd save summary financials analysis options ownership company history related open  previous close  volume avg k k days range  wk range  market cap m dividend rate  yield  beta  shares outstanding m pe ratio eps  recent news fake news infiltrates financial markets financial times  key executives for immunocellular therapeutics ltd bloomberg  briefempery asset management reports  pct passive stake in immunocellular therapeutics  sec filing‍ reuters  todays research reports on stocks to watch capricor therapeutics and immunocellular therapeutics nasdaq  immunocellular therapeutics imuc prices offering of convertible preferred stock and warrants streetinsider  briefempery asset management reports  pct passive stake in immunocellular therapeutics  sec filing‍ reuters  briefimmunocellular therapeutics announces pricing of public offering of convertible preferred stock and warrants reuters  immunocellular prices equity offering shares down  seeking alpha  immunocellular therapeutics announces pricing of public offering of convertible preferred stock and warrants morning star  immunocellular therapeutics announces pricing of public offering of convertible preferred stock and warrants nasdaq  immunocellular therapeutics ltd  other events form k  traders  days ago taking a fresh look at immunocellular therapeutics ltd imuc ci news  days ago chelsea winger pedro suffered multiple fractures in collision with david ospina ismboardcom  days ago intel core coffee lake cpuz screenshot leaked ismboardcom  days ago revenue estimates analysis of immunocellular therapeutics ltd imuc nolopodrasdejardevercom  days ago revenue estimates analysis of immunocellular therapeutics ltd imuc newsoraclecom  days ago immunocellular therapeutics ltd imuc receives an update from brokers desotoedgecom  immunocellular therapeutics ltd  amendments to articles of inc or bylaws change in fiscal year financial statements and exhibits form k  traders  adchoices adchoices adchoices markets dow dow ▲    last updated time   pm edt markets nasdaq nasdaq ▼    ftse  ftse  ▼    nyse composite nyse composite ▼    adchoices feedback send feedback provide feedback report a problem we appreciate your input select a category im having problems with top destinations im having issues searching im having problems with featured apps i see an error in the content other how we can improve please give an overall site rating submit close privacy statement help help  support flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     imuc key statistics  immunocellular therapeutics ltd financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close immunocellular therapeutics ltd nyse american imuc go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus immunocellular therapeutics ltd after hours  quotes are delayed by  min jul    pm imuc quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description immunocellular therapeutics ltd is a clinicalstage company which engages in the development of immunebased therapies for the treatment of cancers its lead product candidate ict is a dendritic cellbased immunotherapy targeting multiple tumorassociated antigens on glioblastoma stem cells immunocellular therapeutics ltd is a clinicalstage company which engages in the development of immunebased therapies for the treatment of cancers its lead product candidate ict is a dendritic cellbased immunotherapy targeting multiple tumorassociated antigens on glioblastoma stem cells its pipeline also includes ict a patientspecific dendritic cellbased immunotherapy targeting the cd antigen on stem cells in recurrent glioblastoma ict a patientspecific dendritic cellbased immunotherapy targeting antigens on ovarian cancer stem cells and the stemtotcell research program which engineers the patients hematopoietic stem cells to generate antigenspecific cancerkilling t cells the company was founded on january   and is headquartered in calabasas ca valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr gary s titus   chairman  secretary dr anthony j gringeri   president chief executive officer  director mr david e fractor   chief financial officer dr steven j swanson   senior vice presidentresearch dr john s yu   director insider actions – purchase – sale  – number of transactions  date name shares transaction value  andrew gengos director    derivativenonderivative trans at  per share   andrew gengos director    award at  per share   anthony j gringeri senior vp strategic resources    award at  per share   david e fractor vp of finance    award at  per share   steven j swanson senior vice president researc    award at  per share   andrew gengos director    acquisition at  per share   john s yu director    gift at  per share   john s yu director    derivativenonderivative trans at  per share   john s yu director    gift at  per share   john s yu director    derivativenonderivative trans at  per share   gary s titus director    award at  per share   rahul singhvi director    award at  per share   andrew gengos director    award at  per share   anthony j gringeri senior vp strategic resources    award at  per share   david e fractor vp of finance    award at  per share   andrew gengos director    acquisition at  per share   anthony j gringeri senior vp strategic resources    acquisition at  per share   anthony j gringeri senior vp strategic resources    acquisition at  per share   gary s titus director    acquisition at  per share   gary s titus director    acquisition at  per share  newslatestcompanyusimuc marketwatch news on imuc tesla gains after safety rating supernus surges  pm dec    wallace witkowski calamp immunocellular darden are stocks to watch  am dec    wallace witkowski calamp drops immunocellular rises after hours  pm dec    wallace witkowski stock futures edge up after retail claims data  am dec    victor reklaitis immunocellular plunges  on cancerdrug news  am dec    barbara kollmeyer facebook shares jump on sp  inclusion  pm dec    wallace witkowski immunocellular shares fall  after study result  pm dec    wallace witkowski immunocellular therapeutics rises  in premarket  am jan    steve gelsi immunocellular prices offering at  discount  am oct    marketwatchcom thursday’s biggest gaining and declining stocks  pm sept    greg morcroft wednesday’s biggest gaining and declining stocks  pm aug    marketwatch tuesday’s top gaining and declining stocks  pm aug    marketwatch hot stocks to watch  am aug    marketwatchcom stocks to watch tuesday church  dwight nordson  am aug    marketwatch urban outfitters shares rally after hours  pm aug    carla mozee immunocellular therapeutics ceo resigns  pm aug    marketwatchcom thursday’s biggest gaining and declining stocks  pm may    marketwatch newsnonmarketwatchcompanyusimuc other news on imuc att harleydavidson skid into tuesday’s week low club  pm july    wallstcom immunocellular prices equity offering shares down   am july    seeking alpha  things in biotech you should learn today june    am june    seeking alpha immunocellular suspends patient randomization in latestage study of ict due to lack of money  am june    seeking alpha immunocellular down  on money woes  pm may    seeking alpha  different companies with  different approaches to tumors  pm april    gurufocuscom calling time on biotechs shady stockpromotion schemes  pm april    seeking alpha immunocellular therapeutics imuc ceo anthony gringeri on q  results  earnings call transcript  pm march    seeking alpha k immunocellular therapeutics ltd  pm march    edgar online  edg  q k immunocellular amends protocol of latestate study of lead product candidate to allow for faster randomization shares ahead  premarket  am march    seeking alpha northwest biotherapeutics could be a jewel among lowpriced biotechs  am dec    seeking alpha biggest movers in manufacturing stocks now – vcel auph onvo cc  pm dec    investorplacecom biggest movers in manufacturing stocks now – vblt cphr tho prcp  am nov    investorplacecom hottest manufacturing stocks now – fate epzm rgnx vhi  am nov    investorplacecom hottest manufacturing stocks now – enta ktec mov mt  am nov    investorplacecom biggest movers in manufacturing stocks now – crbp stml imuc ocip  pm nov    investorplacecom immunocellular therapeutics imuc ceo andrew gengos on q  results  earnings call transcript  pm nov    seeking alpha  biotech stocks that are broker favorites  am sept    zackscom immunocellular therapeutics imuc ceo andrew gengos on q  results  earnings call transcript  pm aug    seeking alpha q immunocellular therapeutics ltd  pm aug    edgar online  edg  q k loading more headlines at a glance immunocellular therapeutics ltd  calabasas road suite  calabasas california  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for imuc newspressreleasecompanyusimuc press releases on imuc todays research reports on stocks to watch capricor therapeutics and immunocellular therapeutics  am july    accesswire immunocellular therapeutics announces pricing of public offering of convertible preferred stock and warrants  am july    pr newswire  prf deadline today levi  korsinsky llp reminds immunocellular therapeutics ltd shareholders of a class action lawsuit and a lead plaintiff deadline of june    imuc  am june    accesswire immunocellular therapeutics receives notice from nyse mkt for noncompliance with continued listing standards  pm june    pr newswire  prf deadline tomorrow khang  khang llp announces a securities class action lawsuit against immunocellular therapeutics ltd and reminds investors with losses to contact the firm  pm june    accesswire act now  deadline tomorrow monteverde  associates pc reminds investors of a class action filed on behalf of immunocellular therapeutics ltd shareholders and a lead plaintiff deadline of june    imuc  pm june    accesswire deadline tomorrow the klein law firm reminds investors of a class action filed on behalf of immunocellular therapeutics ltd shareholders and a lead plaintiff deadline of june    am june    accesswire imuc alert rosen law firm reminds immunocellular therapeutics ltd investors of important june  deadline in class action  imuc  pm june    pr newswire  prf june  deadline lundin law pc announces a securities class action lawsuit against immunocellular therapeutics ltd and encourages investors with losses to contact the firm  pm june    pr newswire  prf upcoming deadline the law offices of vincent wong reminds investors of a class action involving immunocellular therapeutics ltd and a lead plaintiff deadline of june    am june    accesswire deadline alert bronstein gewirtz  grossman llc notifies investors with over k in losses of class action against immunocellular therapeutics ltd imuc and lead plaintiff deadline  june    am june    accesswire friday june  deadline khang  khang llp announces a securities class action lawsuit against immunocellular therapeutics ltd and reminds investors with losses to contact the firm  pm june    globenewswire the klein law firm reminds investors of a class action filed on behalf of immunocellular therapeutics ltd shareholders and a lead plaintiff deadline of june    am june    globenewswire friday deadline lundin law pc announces a securities class action lawsuit against immunocellular therapeutics ltd and encourages investors with losses to contact the firm  pm june    globenewswire one week deadline khang  khang llp announces a securities class action lawsuit against immunocellular therapeutics ltd and reminds investors with losses to contact the firm  pm june    accesswire equity alert levi  korsinsky llp reminds immunocellular therapeutics ltd shareholders of a class action lawsuit and a lead plaintiff deadline of june    imuc  am june    globenewswire deadline approaching lundin law pc announces a securities class action lawsuit against immunocellular therapeutics ltd and encourages investors with losses to contact the firm  pm june    accesswire day deadline khang  khang llp announces a securities class action lawsuit against immunocellular therapeutics ltd and reminds investors with losses to contact the firm  pm june    accesswire shareholder alert levi  korsinsky llp reminds immunocellular therapeutics ltd shareholders of a class action lawsuit and a lead plaintiff deadline of june    imuc  am june    accesswire immunocellular therapeutics provides update on strategic review and decision to suspend further patient randomization for ict phase  trial  am june    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  immunocellular therapeutics ltd  imuc  stock price today  zacks imuc is down  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more immunocellular therapeutics ltd imuc delayed data from amex  usd     updated jul    pm et add to portfolio zacks rank style scores na value  na growth  na momentum  na vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank top  out of  industry medical  biomedical and genetics view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est na current qtr est na current yr est na exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  biomedical and genetics zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings news for imuc zacks news for imuc other news for imuc  biotech stocks that are broker favorites am est zacks immunocellular imuc am est zacks imuc what are zacks experts saying now zacks private portfolio services more zacks news for imuc pbs socal expands board of trustees with three new members am est pr web european markets finish mostly lower as airlines  autos drop pm est alliance news european shares extend losses on currency woes am est alliance news midday gainers  losers pm est seeking alpha healthcare gainers  losers as of  am am est seeking alpha more other news for imuc premium research for imuc zacks rank na zacks industry rank top  out of  zacks sector rank bottom   out of  style scores na value  na growth  na momentum  na vgm earnings esp  research report for imuc snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank immunocellular therapeutics ltd imuc na bioverativ inc bivv enzo biochem inc enz exelixis inc exel innoviva inc inva vertex pharmaceuticals incorporated vrtx aveo pharmaceuticals inc aveo see all medical  biomedical and genetics peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary immunocellular therapeutics ltd operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens peptide based immunotherapies targeting cancer stem cells and monoclonal antibodies to diagnose and treat several different cancers immunocellular therapeutics ltd is based in california usa immunocellular therapeutics ltd  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports immunocellular therapeutics ltd  product pipeline revi immunocellular therapeutics ltd  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports immunocellular therapeutics ltd  product pipeline review  summaryglobal markets direct’s ‘immunocellular therapeutics ltd  product pipeline review  ’ provides an overview of the immunocellular therapeutics ltd’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of immunocellular therapeutics ltd’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of immunocellular therapeutics ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of immunocellular therapeutics ltd’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the immunocellular therapeutics ltd’s pipeline productsreasons to buy evaluate immunocellular therapeutics ltd’s strategic position with total access to detailed information on its product pipeline assess the growth potential of immunocellular therapeutics ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the immunocellular therapeutics ltd’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of immunocellular therapeutics ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of immunocellular therapeutics ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of immunocellular therapeutics ltd and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures immunocellular therapeutics ltd snapshot immunocellular therapeutics ltd overview key information key facts immunocellular therapeutics ltd  research and development overview key therapeutic areas immunocellular therapeutics ltd  pipeline review pipeline products by stage of development pipeline products  monotherapy immunocellular therapeutics ltd  pipeline products glance immunocellular therapeutics ltd  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities immunocellular therapeutics ltd  early stage pipeline products indcta filed productscombination treatment modalities preclinical productscombination treatment modalities immunocellular therapeutics ltd  drug profiles ict product description mechanism of action rd progress ict product description mechanism of action rd progress ict product description mechanism of action rd progress ict product description mechanism of action rd progress ict product description mechanism of action rd progress ict product description mechanism of action rd progress immunocellular therapeutics ltd  pipeline analysis immunocellular therapeutics ltd  pipeline products by target immunocellular therapeutics ltd  pipeline products by route of administration immunocellular therapeutics ltd  pipeline products by molecule type immunocellular therapeutics ltd  pipeline products by mechanism of action immunocellular therapeutics ltd  recent pipeline updates immunocellular therapeutics ltd  dormant projects immunocellular therapeutics ltd  company statement immunocellular therapeutics ltd  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesimmunocellular therapeutics ltd key information immunocellular therapeutics ltd key facts immunocellular therapeutics ltd  pipeline by indication  immunocellular therapeutics ltd  pipeline by stage of development  immunocellular therapeutics ltd  monotherapy products in pipeline  immunocellular therapeutics ltd  phase ii  immunocellular therapeutics ltd  phase i  immunocellular therapeutics ltd  indcta filed  immunocellular therapeutics ltd  preclinical  immunocellular therapeutics ltd  pipeline by target  immunocellular therapeutics ltd  pipeline by route of administration  immunocellular therapeutics ltd  pipeline by molecule type  immunocellular therapeutics ltd  pipeline products by mechanism of action  immunocellular therapeutics ltd  recent pipeline updates  immunocellular therapeutics ltd  dormant developmental projects list of figuresimmunocellular therapeutics ltd  pipeline by top  indication  immunocellular therapeutics ltd  pipeline by stage of development  immunocellular therapeutics ltd  monotherapy products in pipeline  immunocellular therapeutics ltd  pipeline by top  target  immunocellular therapeutics ltd  pipeline by top  route of administration  immunocellular therapeutics ltd  pipeline by top  molecule type  immunocellular therapeutics ltd  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send